Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of ticilimumab versus dacarbazine or temozolomide in advanced melanoma
2005-002827-15Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2005
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Ticilimumab with Dacarbazine or temozolomide (2 arms). Primary endpoint: Overall survival. Started Oct 2005; status: completed.
02
Drugs
tremelimumabdacarbazinetemozolomide
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-002827-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002827-15.